Diabetes

Announced on May 13, the approval indicates Eli Lilly and Company's novel dual GLP-1/GIP agonist, tirzepatide (Mounjaro), for use as an adjunct to diet and exercise to improve blood sugar in adult patients with type 2 diabetes.

An analysis of data from more than 3500 individuals followed for more than 20 years provides insight into the impact of food insecurity on risk of cardiometabolic conditions, including obesity and type 2 diabetes.

A review of data presented at ATTD 2022 dissects what features within smartphone applications created to improve diabetes management actually contribute to improved glycemic control.

This valuable service can make a meaningful difference.

The role of altered gut microbiota on functions, ranging from hormone secretion to metabolic function, remains unclear.

Many patients with heart failure do not receive optimal therapy until they present to a hospital with exacerbations.

One in 5 American adults with diabetes don't know that they have the disease.

A telehealth intervention may successfully lead to improvements in diabetes management.

Patients taking the blood pressure medication required less insulin and demonstrated immunomodulatory benefits.

More than 45 pharmacies participate in the National Diabetes Program.

Pending FDA approval, insulin from nonprofit pharmaceutical company Civica could be available in 2024.

How can pharmacists help slow the progression of diabetic kidney disease?

PCOS prevalence in girls with type 2 diabetes was almost 20%.

Diabetes-related deaths increased by 17% in 2020 and 15% in 2021.

Two recently published studies have identified increases in T1D in children since the pandemic began.

Researchers evaluated whether early gestational diabetes screening is associated with improved perinatal outcomes.

Managing autoimmune conditions like type 1 diabetes, rheumatoid arthritis, and lupus during pregnancy can present challenges for patients and physicians.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.

Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.

An investigation looks into how the incidence of type 1 diabetes changed during the first year of the COVID-19 pandemic.

A study published in the Journal of the American Academy of Dermatology did a prospective analysis on psoriasis biologic treatment response related to comorbid obesity and a history of diabetes.

Type 1 diabetes requires patients to have knowledge and skill to manage medication and potential complications.

Automation in closed-loop systems improves type 1 diabetes outcomes and glucose profiles in teens, according to a study published in JAMA Pediatrics.

The prevalence of insulin pump use for Black beneficiaries increased from 3.9% to 4.6% between 2017 and 2019.

The addition of a pharmacist to a diabetes management team increases therapy optimization and medication access while enhancing patient care.

Prescription fills decreased most significantly in a subgroup of adults.

Lockdown orders impacted how diabetes care was provided for new onset T1D.

Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.

Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.